UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 33,241 Shares of MiMedx Group, Inc. (NASDAQ:MDXG)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 14.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 196,244 shares of the company’s stock after selling 33,241 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.13% of MiMedx Group worth $1,160,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in MDXG. Isthmus Partners LLC lifted its position in MiMedx Group by 30.4% during the 2nd quarter. Isthmus Partners LLC now owns 393,214 shares of the company’s stock worth $27,000 after acquiring an additional 91,714 shares during the last quarter. Blue Trust Inc. bought a new position in shares of MiMedx Group in the third quarter worth about $30,000. Point72 Asset Management L.P. bought a new position in shares of MiMedx Group in the second quarter worth about $40,000. Entropy Technologies LP acquired a new position in shares of MiMedx Group during the 3rd quarter worth about $64,000. Finally, Quest Partners LLC bought a new stake in MiMedx Group during the 2nd quarter valued at approximately $81,000. Institutional investors and hedge funds own 79.15% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 8th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $12.00.

MiMedx Group Stock Down 4.2 %

MDXG stock opened at $9.13 on Thursday. MiMedx Group, Inc. has a twelve month low of $5.47 and a twelve month high of $10.14. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. The company has a market cap of $1.34 billion, a PE ratio of 16.60 and a beta of 1.98. The business’s 50-day simple moving average is $7.87 and its 200 day simple moving average is $7.06.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.